[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69837975D1 - Diagnostisches Abbildungsverfahren - Google Patents

Diagnostisches Abbildungsverfahren

Info

Publication number
DE69837975D1
DE69837975D1 DE69837975T DE69837975T DE69837975D1 DE 69837975 D1 DE69837975 D1 DE 69837975D1 DE 69837975 T DE69837975 T DE 69837975T DE 69837975 T DE69837975 T DE 69837975T DE 69837975 D1 DE69837975 D1 DE 69837975D1
Authority
DE
Germany
Prior art keywords
contrast agent
moiety
image
peptidic
generating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69837975T
Other languages
English (en)
Other versions
DE69837975T2 (de
Inventor
Jo Klaveness
Helge Tolleshaug
Anne Naevestad
Christopher D Black
Henry R Wolfe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
GE Healthcare AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare AS filed Critical GE Healthcare AS
Application granted granted Critical
Publication of DE69837975D1 publication Critical patent/DE69837975D1/de
Publication of DE69837975T2 publication Critical patent/DE69837975T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1255—Granulates, agglomerates, microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
DE69837975T 1997-04-24 1998-04-24 Diagnostisches Abbildungsverfahren Expired - Lifetime DE69837975T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9708265 1997-04-24
GBGB9708265.5A GB9708265D0 (en) 1997-04-24 1997-04-24 Contrast agents

Publications (2)

Publication Number Publication Date
DE69837975D1 true DE69837975D1 (de) 2007-08-02
DE69837975T2 DE69837975T2 (de) 2008-02-28

Family

ID=10811256

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69824842T Expired - Lifetime DE69824842T2 (de) 1997-04-24 1998-04-24 Kontrastmittel, die auf angiogenese-rezeptoren zielen
DE69837975T Expired - Lifetime DE69837975T2 (de) 1997-04-24 1998-04-24 Diagnostisches Abbildungsverfahren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69824842T Expired - Lifetime DE69824842T2 (de) 1997-04-24 1998-04-24 Kontrastmittel, die auf angiogenese-rezeptoren zielen

Country Status (10)

Country Link
US (2) US6610269B1 (de)
EP (2) EP1442751B1 (de)
JP (1) JP4993419B2 (de)
AT (2) ATE365054T1 (de)
AU (1) AU7068798A (de)
DE (2) DE69824842T2 (de)
DK (1) DK1442751T3 (de)
ES (2) ES2224379T3 (de)
GB (1) GB9708265D0 (de)
WO (1) WO1998047541A1 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
US6245318B1 (en) 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
EP1068224B1 (de) 1998-03-31 2005-05-11 Bristol-Myers Squibb Pharma Company Pharmazeutika zur bildgebung der angiogenischen krankheiten
DE19845798A1 (de) * 1998-09-29 2000-04-13 Schering Ag Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
US6284223B1 (en) * 1998-10-15 2001-09-04 Fluoroprobe, Inc. Method for viewing tumor tissue located within a body cavity
US6652836B2 (en) 1998-10-15 2003-11-25 Fluoroprobe, Inc. Method for viewing tumor tissue located within a body cavity
US6299860B1 (en) 1998-10-15 2001-10-09 Fluoro Probe, Inc. Method for viewing diseased tissue located within a body cavity
IL142958A0 (en) 1998-12-18 2002-04-21 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
TR200101757T2 (tr) 1998-12-18 2001-12-21 Dupont Pharmaceuticais Company Vitronektin reseptör antagonisti farmasötikler
DE19924138A1 (de) 1999-05-26 2000-11-30 Henkel Kgaa Lösbare Klebeverbindungen
GB9922173D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CA2387767A1 (en) * 1999-10-15 2001-04-26 Henricus P. C. Hogenkamp Cobalamin conjugates useful as imaging and therapeutic agents
DE19951599A1 (de) * 1999-10-27 2001-05-23 Henkel Kgaa Verfahren zur adhesiven Trennung von Klebeverbunden
AU2001227837A1 (en) * 2000-01-12 2001-07-24 Light Sciences Corporation Novel treatment for eye disease
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US6989139B2 (en) * 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
PT1272507E (pt) * 2000-04-12 2005-11-30 Amersham Health As Derivados de peptidos para ligacao a integrina
EP2279757A3 (de) * 2000-06-02 2011-08-03 Bracco Suisse SA Arzneimitteln zum Targeting von Endothelzellen
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
AU2001275210B2 (en) 2000-06-02 2006-09-28 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates
AU7002501A (en) * 2000-06-21 2002-01-02 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
DE10037884A1 (de) * 2000-08-03 2002-02-21 Henkel Kgaa Verfahren zur beschleunigten Klebstoffaushärtung
NO20004795D0 (no) 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
BRPI0210886B8 (pt) 2001-07-10 2021-05-25 Amersham Health As composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
US7087212B2 (en) * 2001-08-17 2006-08-08 Mallinckrodt, Inc Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
US20030100830A1 (en) * 2001-11-27 2003-05-29 Sheng-Ping Zhong Implantable or insertable medical devices visible under magnetic resonance imaging
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7666979B2 (en) 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
EP1369134A1 (de) * 2002-06-05 2003-12-10 Bracco Imaging S.p.A. Mittel fur magnetisches Bildformungsverfahren
JP2004138397A (ja) * 2002-10-15 2004-05-13 Kyowa Hakko Kogyo Co Ltd 特定部位に集積する化合物のスクリーニング方法
AU2004217894B2 (en) 2003-03-03 2010-07-15 Bracco International B.V. Peptides that specifically bind HGF receptor (cMet) and uses thereof
JP2007521254A (ja) * 2003-06-25 2007-08-02 ゲルベ 診断画像用化合物
FR2856689A1 (fr) * 2003-06-25 2004-12-31 Guerbet Sa Composes specifiques a forte relaxivite
NO20034350D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av kolorektal kreft
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
US7431915B2 (en) * 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
WO2011008992A2 (en) * 2009-07-15 2011-01-20 The Regents Of The University Of California Peptides whose uptake in cells is controllable
US7985401B2 (en) * 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
NO20035681D0 (no) * 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av lungekreft
NO20035683D0 (no) * 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av prostatakreft
NO20035682D0 (no) * 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av ösofagkreft og Barretts ösofag
NO20035748D0 (no) * 2003-12-19 2003-12-19 Amersham Health As Optisk avbildning av sårbar arteriosklerose
US20070098631A2 (en) * 2004-04-28 2007-05-03 Guerbet Diagnostic compounds comprising a scaffold coupled to a signal entity for medical imaging diagnostic
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US20050281798A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue using composition
US20050281799A1 (en) 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue using compositions
US7553810B2 (en) * 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US20050281739A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue using compositions
US7608579B2 (en) * 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
WO2006014567A2 (en) * 2004-07-08 2006-02-09 Pneumrx, Inc. Pleural effusion treatment device, method and material
DE602004009169D1 (de) * 2004-07-22 2007-11-08 Bayer Schering Pharma Ag Verwendung von Cyanin-farbstoffen zur Diagnose von Krankheiten, welche mit Angiogenese assoziert sind
GB0421308D0 (en) * 2004-09-24 2004-10-27 Amersham Plc Enzyme inhibitor imaging agents
JP2008534617A (ja) * 2005-04-01 2008-08-28 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム キレート剤としてのポリ（ペプチド）：製造方法および用途
CA2606270A1 (en) * 2005-04-19 2006-10-26 Massachusetts Institute Of Technology Amphiphilic polymers and methods of use thereof
WO2007030012A2 (en) * 2005-09-05 2007-03-15 Stichting Voor De Technische Wetenscahappen Extracellular matrix imaging
US20070140974A1 (en) * 2005-12-15 2007-06-21 General Electric Company Targeted nanoparticles for magnetic resonance imaging
EP1986682B1 (de) * 2006-02-06 2013-08-28 The Burnham Institute for Medical Research Verfahren und zusammensetzungen in verbindung mit targeting von tumoren und wunden
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
WO2008036763A2 (en) * 2006-09-20 2008-03-27 Pneumrx, Inc. Tissue adhesive compositions and methods thereof
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
WO2008136869A2 (en) 2006-12-06 2008-11-13 Burnham Institute For Medical Research Methods and compositions related to targeting wounds, regenerating tissue, and tumors
JP2010514839A (ja) 2007-01-03 2010-05-06 バーナム インスティテュート フォー メディカル リサーチ クロット結合化合物に関連する方法および組成物
DE102007036570A1 (de) 2007-08-03 2009-02-19 Siemens Ag Screeningtest zur Erkennung von Prostataerkrankungen sowie Vorrichtung und Diagnosesubstanz zur Durchführung des Tests
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
DE102007041836A1 (de) * 2007-09-03 2009-03-05 Siemens Ag Verfahren zur Abbildung eines Prostatatumors und dafür geeignetes Kontrastmittel
US20090074672A1 (en) * 2007-09-17 2009-03-19 Sri International Tumor Boundary Imaging
US8463365B2 (en) 2007-09-19 2013-06-11 Oncofluor, Inc. Method for imaging and treating organs and tissues
US20100143258A1 (en) * 2008-12-05 2010-06-10 General Electric Company Tumor margin imaging agents
WO2010075540A1 (en) * 2008-12-23 2010-07-01 Burnham Institute For Medical Research Methods and compositions for synaphically-targeted treatment for cancer
JP2012513589A (ja) 2008-12-23 2012-06-14 ジーイー・ヘルスケア・リミテッド 骨髄イメージング剤としての９９ｍＴｃ−ペプチド系化合物の応用
US11235062B2 (en) * 2009-03-06 2022-02-01 Metaqor Llc Dynamic bio-nanoparticle elements
US11096901B2 (en) 2009-03-06 2021-08-24 Metaqor Llc Dynamic bio-nanoparticle platforms
JP2013507365A (ja) 2009-10-07 2013-03-04 サンフォード−バーナム メディカル リサーチ インスティテュート 血餅結合脂質化合物に関する方法および組成物
WO2011049964A1 (en) 2009-10-19 2011-04-28 Lab Scientific Group Rna detection and quantitation
JP2013515008A (ja) 2009-12-18 2013-05-02 サンフォード−バーナム メディカル リサーチ インスティテュート 凝血塊結合化合物に関連する方法および組成物
EP2515944B1 (de) 2009-12-23 2020-04-22 Sanford-Burnham Medical Research Institute Verfahren und zusammensetzungen im zusammenhang mit annexin 1-bindenden verbindungen
EP2555802A1 (de) 2010-04-08 2013-02-13 Sanford-Burnham Medical Research Institute Verfahren und zusammensetzungen zur optimierten freisetzung von verbindungen
WO2012136813A2 (en) 2011-04-07 2012-10-11 Universitetet I Oslo Agents for medical radar diagnosis
EP2717909B1 (de) 2011-06-04 2017-12-06 Rochester General Hospital Research Institute Zusammensetzungen und verfahren in zusammenhang mit p6 von haemophilus influenzae
US20140308342A1 (en) 2011-11-11 2014-10-16 Yale University Reprogramming urokinase into an antibody-recruiting anticancer agent
US10029017B2 (en) 2013-01-29 2018-07-24 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
CA3128911C (en) 2013-01-30 2023-10-17 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
EP3164420A4 (de) * 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Gerichtete konjugate sowie partikel und formulierungen davon
ES2828954T3 (es) 2014-09-17 2021-05-28 Fluoguide As Péptido de localización específica de uPAR para su uso en la formación peroperatoria de imágenes ópticas de cáncer invasivo
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
EP3037820A1 (de) * 2014-12-27 2016-06-29 Miltenyi Biotec GmbH Zellerkennungsverfahren und Reagenzien mit lösbarem Etikettierungsteil
US20180221513A1 (en) * 2015-03-16 2018-08-09 Northwestern University Contrast-agent-labeled peptide amphiphile nanofibers
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
US10548881B2 (en) 2016-02-23 2020-02-04 Tarveda Therapeutics, Inc. HSP90 targeted conjugates and particles and formulations thereof
WO2018022929A1 (en) * 2016-07-27 2018-02-01 The Trustees Of Columbia University In The City Of New York Gel-bound compositions for radiotherapy and uses thereof
EP3412303A1 (de) 2017-06-08 2018-12-12 Medizinische Universität Innsbruck Verbessertes pharmakokinetik- und cholecystokinin-2-rezeptor (cck2r)-zielverfahren für diagnose und therapie
WO2020198074A1 (en) 2019-03-22 2020-10-01 Reflexion Pharmaceuticals, Inc. D-peptidic compounds for vegf

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
JPH04500823A (ja) * 1989-07-20 1992-02-13 ノバルティス・アクチエンゲゼルシャフト ポリペプチド誘導体
US5183900A (en) 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US6107459A (en) * 1991-02-08 2000-08-22 Diatide, Inc. Technetium-99m labeled peptides for diagnostic imaging
US6004554A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5508020A (en) * 1992-06-05 1996-04-16 Diatech, Inc. Technetium-99M labeled peptides for imaging
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
CN1173991C (zh) * 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
US5512591A (en) * 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
JP3670309B2 (ja) * 1993-04-01 2005-07-13 第一製薬株式会社 二環性複素環化合物
US5480970A (en) 1993-12-22 1996-01-02 Resolution Pharmaceuticals Metal chelators
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
GB9502065D0 (en) * 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
US6027711A (en) * 1995-06-07 2000-02-22 Rhomed Incorporated Structurally determined metallo-constructs and applications
DE19522774A1 (de) * 1995-06-27 1997-01-02 Ifu Gmbh Einrichtung zur spektroskopischen Untersuchung von Proben, die dem menschlichen Körper entnommen wurden
NZ330868A (en) * 1996-02-13 2000-01-28 Zeneca Ltd 4-phenoxy, phenylthio or phenylamino substituted quinazoline derivatives ane medicaments useful as VEGF inhibitors
AU735900B2 (en) * 1996-03-12 2001-07-19 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
JP2000508319A (ja) * 1996-04-10 2000-07-04 メルク エンド カンパニー インコーポレーテッド αｖβ３拮抗薬
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
WO1998018497A2 (en) * 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
IL131655A0 (en) * 1997-03-04 2001-01-28 Bio Technology General Corp Isolation of tissue specific ligands and their use for targeting pharmaceuticals to organs
EP1056773A2 (de) 1998-02-11 2000-12-06 Resolution Pharmaceuticals Inc. Für angiogenese spezifische moleküle

Also Published As

Publication number Publication date
DE69837975T2 (de) 2008-02-28
WO1998047541A1 (en) 1998-10-29
ES2224379T3 (es) 2005-03-01
JP2002511845A (ja) 2002-04-16
EP0977600B1 (de) 2004-06-30
ES2287599T3 (es) 2007-12-16
JP4993419B2 (ja) 2012-08-08
US7413727B2 (en) 2008-08-19
ATE270116T1 (de) 2004-07-15
US20040009122A1 (en) 2004-01-15
EP1442751A1 (de) 2004-08-04
GB9708265D0 (en) 1997-06-18
AU7068798A (en) 1998-11-13
DE69824842D1 (de) 2004-08-05
US6610269B1 (en) 2003-08-26
EP0977600A2 (de) 2000-02-09
DK1442751T3 (da) 2007-09-24
ATE365054T1 (de) 2007-07-15
DE69824842T2 (de) 2005-11-17
EP1442751B1 (de) 2007-06-20

Similar Documents

Publication Publication Date Title
DE69837975D1 (de) Diagnostisches Abbildungsverfahren
ATE314097T1 (de) Kontrastmittel
WO1998018497A3 (en) Contrast agents
CY1119742T1 (el) Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου
PT907379E (pt) Agentes de contraste bioactivados para imagiologia de diagnostico
CY1109151T1 (el) Αντισωματα dr4 και χρησεις αυτων
DE68926708D1 (de) Von einem rezeptor induziertes kontrastmittel für den endocytose-typ mri
IT1270882B (it) Oligopeptidi ad attivita' fungicida
DK0640622T3 (da) Polysaccharidderivat og lægemiddelbærer
DE69619526D1 (de) Fgf9 als spezifischer ligand für fgfr3
ES2110097T3 (es) Sistema de liberacion basado en proteinas.
BRPI0518328A2 (pt) agente de contraste, composiÇço farmacÊutica, uso de um agente de contraste, mÉtodo para gerar imagens realÇadas de um corpo animal ou humano, e, kit para a preparaÇço de um composiÇço radiofarmacÊutica
ATE425770T1 (de) Kontrastmittel
DE69616453D1 (de) Liposomensuspensionen als blut-pool-kontrastmittel
DK0451612T3 (da) Anti-Oncostatin M monoklonale antistoffer
Kalow The lymphocyte calcium test for diagnosis of susceptibility to malignant hyperthermia.
BR0107845A (pt) Diagnóstico do risco de uma pessoa desenvolver alcoolismo
ITVI930179A0 (it) Paratendini per cavalli di tipo perfezionato
ITMI921539A1 (it) Imbracatura per animali tenuti a guinzaglio

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: HAMMONDS LLP, LONDON, GB

R082 Change of representative

Ref document number: 1442751

Country of ref document: EP

Representative=s name: J D REYNOLDS & CO., GB